TEVA, US8816242098

Teva stock: At 4.31 percent below its high, Teva stock traded at USD 40.21 on October 22

Published on 10/23/2026 at 15:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays kept Overweight at USD 47.00 on October 15, 2026. Teva stock was USD 40.21 on October 22, 2026 at 4:00 p.m. ET, down 1.01 percent on NYSE.

Price position and targets

Teva traded 4.31 percent below its 52-week high on October 22, 2026.
Barclays raised its target from USD 42.00 to USD 47.00 on October 15, 2026.
Teva stock was USD 40.21 on October 22, 2026 at 4:00 p.m. ET, down 1.01 percent on the NYSE.
Teva is scheduled to report third-quarter 2026 results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries (ISIN US8816242098) last stood at USD 40.21 on the NYSE on October 22, 2026 at 4:00 p.m. ET, down 1.01 percent from the USD 40.62 prior close. The stock was 4.31 percent below its USD 42.02 52-week high, making the distance to the yearly peak the clearest near-term valuation marker.

Barclays target remains above price

Barclays raised its target for Teva from USD 42.00 to USD 47.00 and maintained an Overweight rating on October 15, 2026, MarketBeat reported. The new target stands 16.88 percent above the October 22 price, calculated in the same currency.

Price remains below yearly peak

Teva's USD 18.88 to USD 42.02 52-week range places the latest USD 40.21 level 4.31 percent below the high and 113.04 percent above the low. Market capitalization stood at USD 46.9 billion on October 22, 2026, while the company profile identifies Teva as a healthcare business focused on specialty and generic drugs.

What comes next for Teva

Teva is scheduled to publish its third-quarter 2026 results on November 3, 2026, with the release planned for 7:00 a.m. ET and the conference call for 8:00 a.m. ET, according to the company's press release dated September 23, 2026. The latest reported quarter ended June 30, 2026, with revenue of USD 4.14 billion, according to MarketBeat.

A dated closing level

Teva last traded at USD 40.21 on the NYSE on October 22, 2026 at 4:00 p.m. ET, down 1.01 percent versus the USD 40.62 prior close. The next scheduled company date is November 3, 2026.